Compare ONEW & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | UNCY |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.6M | 145.3M |
| IPO Year | 2019 | 2021 |
| Metric | ONEW | UNCY |
|---|---|---|
| Price | $10.18 | $6.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $16.50 | ★ $25.67 |
| AVG Volume (30 Days) | 87.8K | ★ 661.2K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | $675,000.00 |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $3.14 | $582.86 |
| P/E Ratio | $3.92 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $8.12 | $0.47 |
| 52 Week High | $17.92 | $8.74 |
| Indicator | ONEW | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 41.89 |
| Support Level | $10.07 | $6.17 |
| Resistance Level | $10.59 | $7.22 |
| Average True Range (ATR) | 0.62 | 0.54 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 27.65 | 5.83 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.